Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.01.01.697288

TMEM33 deletion potentiates anti-tumor CD8+ T cell immunity

Abstract

Improving responses to cancer immunotherapies requires deeper insight into the cellular mechanisms governing T cell-mediated anti-tumor immunity. TMEM33 is an endoplasmic reticulum-resident transmembrane protein enriched across multiple tumor types, with reported functions in anti-viral immunity as well as calcium and lipid homeostasis, yet its role in tumor immunosurveillance remains unknown. Using murine genetic models, we demonstrate that host TMEM33 constrains anti-tumor CD8+ T cell responses. Constitutive Tmem33-/- mice exhibited delayed melanoma tumor growth and increased CD8+ T cell infiltration. Antigen-specific CD8+ compartments in tumors of Tmem33-/- mice showed TCF-1+PD-1+ progenitor-exhausted cell (Tpex) enrichment, elevated effector function and reduced exhaustion, alongside improved effector memory expansion and T-bet expression in draining lymph nodes. We highlight that TMEM33 functions intrinsically within the T cell compartment, as TMEM33 deletion (1) enhanced polyclonal activation of naive CD8+ T cells ex vivo, (2) promoted preferential Tpex accumulation among adoptively transferred naive OT-I cells in B16F10-OVA tumors and draining lymph nodes, and (3) improved the potency of ex vivo-expanded OT-I cells in controlling tumor growth during adoptive cell therapy. Finally, in a large, prospectively recruited metastatic melanoma cohort, lower TMEM33 expression in patient CD8+ T cells significantly correlated with improved survival and elevated TCF-7 (encoding TCF-1). Collectively, our findings define TMEM33 as a formerly unrecognized intrinsic determinant of tumor-directed CD8+ T cell fate that limits Tpex maintenance, and restrains cell therapy responses, suggesting that its modulation may strengthen immunotherapeutic efficacy. One sentence summaryTMEM33 intrinsically limits progenitor exhausted CD8+ T cells, scales anti-tumor responses and predicts melanoma patient survival.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jackson, M. T., Zhao, T., Milotay, G., Pedroza-Pacheco, I., Cai, Y., Willis, C., Phyu, S. M., Beernaert, B., Kwon, J. T., Estephan, H., Almeida, V. P., Aggelakopoulou, M., Panetti, S., Zierhut, C., Elliott, T., Adamopoulou, E., Rehwinkel, J., Sim, M. J., Grover, A., Gabrilovich, D. I., Fairfax, B. P., Honore, E., Withers, D. R., Christianson, J. C., Parkes, E. E.. 2026-01-02. TMEM33 deletion potentiates anti-tumor CD8+ T cell immunity. https://doi.org/10.64898/2026.01.01.697288

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Chimeric antigen receptor T cell therapy targeting CD94 for cytotoxic T/NK cell malignancies

Chimeric antigen receptor (CAR) T cell therapy against pan-B-cell antigens is highly effective, but analogous approaches for T-cell lymphomas risk prolonged T-cell aplasia. We developed a CAR-T therapy targeting a post-thymic antigen, CD94, a receptor with restricted expression in normal tissues and immune cells but enriched in cytotoxic T/NK-cell malignancies. Second generation CD94 CAR T cells generated using a specific and high-affinity anti-CD94 monoclonal antibody showed potent and selective cytotoxicity against CD94-positive tumor cells in vitro and completely eradicated NK-cell leukemia xenografts and patient-derived xenograft models of hepatosplenic T-cell lymphoma and NK/T-cell lymphoma in vivo. Incorporation of truncated B-cell maturation antigen (BCMA) as a safety switch enabled rapid elimination of CAR T cells using anti-BCMA T-cell engagers or anti-BCMA antibody-drug conjugate. Super-resolution microscopy demonstrated intracellular sequestration of CD94 by the CAR, preventing fratricide. Collectively, these findings support anti-CD94 CAR-T therapy as a promising and novel treatment for cytotoxic T/NK-cell neoplasms.

immunology↗

Development of lentiviral vectors specifically targeting CD4+ cells

Because of their central role in immunity, CD4+ T cells are a key target for genetic modification in many therapeutic applications, and lentiviral vectors with a VSV-G envelope are often used for this engineering. However, due to their broad tropism, these vectors are inadequate for cell-targeted in vivo gene delivery. Here, we explored using HIV-1 Env, which has a natural tropism towards these cells, as an alternative. We describe a three-plasmid vector production system to incorporate a panel of CCR5- or CXCR4-tropic Envs. These Env proteins are expressed from pCAG, a plasmid with reduced HIV-1 elements. We identify HIV-1 Env-incorporating vectors that can be produced with sufficient titres to specifically transduce primary CD4+ T cells in the context of in vitro mixed populations of peripheral blood mononuclear cells. We show efficient and specific transduction of HIV-1 Env vectors delivering an anti-CD19 chimeric antigen receptor (CAR). We demonstrate functional activity of the generated CD4+ CAR T cells, leading to the targeted killing of B cells in those mixed cell populations. Our methodology enables the production of HIV-1 Env-incorporating lentiviral vectors with defined CD4 targeted delivery, opening avenues for direct in vivo CAR T cell generation.

immunology↗

A Senescence-Like State is associated with the Immunosuppressive Phenotype of Tumor-Infiltrating Regulatory T Cells

Regulatory T (Treg) cells are essential mediators of immune suppression within the tumor microenvironment (TME) and represent a major barrier to effective anti-tumor immunity and to therapeutic efficacy of immune checkpoint inhibitors (ICIs). Cellular senescence is traditionally characterized by stable cell-cycle arrest accompanied by distinct molecular and functional changes, yet whether tumor-infiltrating (TI) Treg cells acquire senescence-associated features and how these features influence their immunosuppressive activity remain poorly understood. Here, we demonstrate that TI-Treg cells exhibit both apoptosis- and senescence-associated phenotype while retaining, and in some cases likely enhancing, their immunosuppressive capacity. Compared with peripheral Treg cells, some TI-Treg cells from solid cancers display elevated canonical senescence-associated markers, including p16 and p21, DNA damage response pathways, senescence-associated secretory phenotype (SASP) and anti-apoptotic BCL-2 family genes, as well as activation of secretion associated beta-galactosidase (SA-beta-Gal). Though physiological Treg senescence leads to diminished immune suppression, TI-Treg cells paradoxically maintain the expression of key immunosuppressive molecules. These findings identify a previously unrecognized senescence-like state in TI-Treg cells that is functionally distinct from the loss of fitness typically associated with senescence in other cell types or aging-associated Treg senescence. Our study establishes senescence-associated reprogramming as a defining feature of TI-Treg cells and highlights the senescence-like state of Treg cells as a potential therapeutic target for selectively disrupting tumor immune suppression while preserving systemic immune homeostasis.

immunology↗